Home » Topics » Disease categories and therapies » Gastrointestinal

Gastrointestinal
RSS

New therapeutic agents for gastrointestinal disorders revealed

Sep. 28, 2005

MicroRNA --a compelling target for anti-HCV therapy

Sep. 27, 2005

HCV RNA polymerase inhibitors claimed in Japan Tobacco patent

Sep. 27, 2005

XTLbio licenses anti-HCV compounds and technology from VivoQuest

Sep. 26, 2005

GSK's Zefix approved in Japan for HBV-associated cirrhosis

Sep. 26, 2005

Xoma signs manufacture agreement for Cubist's HepeX-B biologic

Sep. 26, 2005

Remicade now approved in U.S. for ulcerative colitis

Sep. 20, 2005

Novel NS5B polymerase inhibitor with in vitro efficacy and in vivo bioavailability

Sep. 20, 2005

KOS-2187: Novel motilide chosen as a clinical candidate

Sep. 20, 2005

Phase II data on the benefits of once-daily SPD-476 in ulcerative colitis

Sep. 19, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....